{"disease":{"id":"mds-and-allogeneic-stem-cell-transplantation","name":"mds and allogeneic stem cell transplantation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04801563","title":"Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT07094464","title":"Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Daihong Liu","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}